SARS-CoV-2 infects host cells through interactions of the spike (S) protein receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) receptors of the host. Therefore, the S RBD-ACE2 binding site is a potential target for the development of anti-SARS-CoV-2 therapies.